AscellaHealth Announces its Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
October 17, 2024 06:00 ET
|
AscellaHealth, LLC; CHAPPER healthcare
AscellaHealth Announces Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
October 16, 2024 10:00 ET
|
AscellaHealth, LLC
Optime Care Broadens Partnership with Rigel Pharmaceuticals for Expanded Commercial Distribution of TAVALISSE®
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
October 15, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre (OHC) as Chair of its Advisory Council
October 15, 2024 02:00 ET
|
Oxford-Harrington Rare Disease Centre
Lord Cameron will lead international efforts to drive the OHC’s mission of delivering 40 new therapies for rare diseases into clinical trials over the next ten years OXFORD, UK and CLEVELAND,...
GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies
October 14, 2024 06:02 ET
|
GEn1E Lifesciences Inc.
GEn1E Lifesciences today announced the publication of a landmark study in the prestigious Journal of Pharmacology and Experimental Therapeutics (JPET)
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
October 11, 2024 07:00 ET
|
NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
October 11, 2024 01:00 ET
|
NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
Nucleic Acid Therapeutics CDMO Industry Outlook, 2024-2030 - Increasing Demand for One-Stop-Shop CDMOs and Growing FDIs in Nucleic Acid Therapeutics
October 10, 2024 12:30 ET
|
Research and Markets
Dublin, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering.The...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
October 10, 2024 01:00 ET
|
Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
October 08, 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...